Home » Stocks » Cardiff Oncology

Cardiff Oncology, Inc. (CRDF)

Stock Price: $6.46 USD 0.35 (5.73%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 128.99M
Revenue (ttm) 250,315
Net Income (ttm) -16.60M
Shares Out 19.97M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $6.46
Previous Close $6.11
Change ($) 0.35
Change (%) 5.73%
Day's Open 6.20
Day's Range 6.20 - 6.71
Day's Volume 834,896
52-Week Range 0.70 - 6.85

More Stats

Market Cap 128.99M
Enterprise Value 121.24M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.97M
Float 9.73M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -1.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 545,359
Short Ratio 1.12
Short % of Float 5.00%
Beta 1.46
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 515.33
PB Ratio 18.49
Revenue 250,315
Operating Income -16.84M
Net Income -16.60M
Free Cash Flow -13.34M
Net Cash 7.76M
Net Cash / Share 0.39
Gross Margin -4,361.55%
Operating Margin -6,727.03%
Profit Margin -4,745.80%
FCF Margin -5,331.06%
ROA -79.89%
ROE -209.71%
ROIC -5,695.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.50*
(124.46% upside)
Low
6.00
Current: $6.46
High
23.00
Target: 14.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.240.380.510.380.310.280.260.450.260.27
Revenue Growth-35.34%-25.14%32.63%21.82%11.65%8.07%-42.44%74.78%-3%-
Gross Profit0.24-0.22-1.31-1.35-0.320.260.260.450.260.27
Operating Income-16.68-17.29-25.60-40.15-25.27-14.95-10.69-4.85-2.98-5.38
Net Income-16.41-16.46-24.91-39.20-27.47-14.33-11.81-11.57-2.24-5.45
Shares Outstanding5.972.330.480.420.360.260.240.180.130.10
Earnings Per Share-2.80-8.26-51.76-93.30-87.12-63.36-50.40-64.08-16.56-56.16
Operating Cash Flow-13.27-13.20-23.28-31.04-22.12-12.73-7.32-4.93-1.93-2.09
Capital Expenditures-0.070.02-0.10-0.82-2.23-0.30-0.65-0.27--0.03
Free Cash Flow-13.34-13.18-23.38-31.86-24.35-13.03-7.97-5.20-1.93-2.12
Cash & Equivalents10.2011.458.2337.8967.4927.2925.8410.820.700.06
Total Debt1.73-1.3316.5416.4714.950.52--2.34
Net Cash / Debt8.4711.456.8921.3651.0212.3425.3210.820.70-2.28
Assets13.0914.1712.2843.9571.4528.9027.1611.671.040.51
Liabilities5.784.095.7824.1822.7420.556.769.505.275.51
Book Value7.3110.086.5119.7748.708.3520.392.17-4.23-5.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cardiff Oncology, Inc.
Country United States
Employees 12
CEO Mark Erlander

Stock Information

Ticker Symbol CRDF
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRDF

Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.